{"schema_version":"1.0","type":"article","title":"Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.md","lang":"zh-Hant","date":"2026-06-04","publish_at":"2026-06-04T10:30:00+08:00","updated_at":"2026-06-04","category":"商業分析系列","topic":"公司研究","tags":["Retatrutide","Eli Lilly","肥胖治療","GLP-1","GIP","Glucagon","減重藥"],"summary":"Eli Lilly 的 retatrutide 在三期試驗中把減重幅度推向接近手術級別，代表肥胖治療正從單一路徑抑制食慾，走向多受體代謝調控的新戰場。","key_points":[],"facts":[],"sections":["藥時事 與 CMoney 全曜財經共同打造減肥藥賽道投資課程","01｜Retatrutide 為什麼比現有 GLP-1 更強？","02｜TRIUMPH-1：不只平均減重，還把很多人帶離肥胖區間","03｜真實世界更重要：中途停藥、反彈、依從性，才是慢性病藥物的真正考驗","04｜安全性仍是關鍵：療效越強，越要看耐受性","05｜真正的戰場，不只是體重，而是心血管、睡眠呼吸中止症與關節疼痛","06｜Retatrutide 對 Lilly 的意義：不是取代 Zepbound，而是建立代謝藥物艦隊","07｜全球三重受體藥物競賽正式進入關鍵窗口","08｜台灣可以怎麼看？康霈與奧孟亞，不在主戰場硬碰硬，而是切 GLP-1 外溢需求","結語｜Retatrutide 不是終點，而是肥胖治療升級的開始"],"references":[],"images":[{"alt":"Retatrutide 透過 GIP、GLP-1 與 glucagon 三重受體機制，把肥胖治療推向接近手術級別的減重幅度。","url":"https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-01.webp"},{"alt":"肥胖藥物競爭已從單純降體重，進入代謝改善、長期維持、安全性與商業化定位的綜合戰場。","url":"https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-02.webp"},{"alt":"Eli Lilly 的三重受體策略，正在重新拉高 GLP-1 類藥物後續競爭門檻。","url":"https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-03.png"},{"alt":"當藥物療效逼近減重手術，醫療支付、慢病管理與藥廠估值邏輯都會被重新定義。","url":"https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-04）。Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場。https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}